A Professional & Personal Networking Site for Cardiologists Worldwide
Sanofi Drug for Heart Rhythm Disorder Is Approved
The Food and Drug Administration approved a new drug Thursday to treat the heart rhythm disorder known as atrial fibrillation, which affects an estimated 2.5 million people in this country, most of them elderly.
The action was welcome news for the drug’s maker, Paris-based Sanofi-Aventis, which hopes the medicine will be a blockbuster and help replace declining revenue as drugs that now account for 20 percent of its sales lose their patent protection in the next few years.
“We’re very happy to get the approval — it’s the first major anti-arrhythmic drug in 10 years,” said Dr. Paul Chew, chief medical and science officer for Sanofi-Aventis in the United States .
More at NYTimes
What are your comments and experienced on Dronedarone?
The action was welcome news for the drug’s maker, Paris-based Sanofi-Aventis, which hopes the medicine will be a blockbuster and help replace declining revenue as drugs that now account for 20 percent of its sales lose their patent protection in the next few years.
“We’re very happy to get the approval — it’s the first major anti-arrhythmic drug in 10 years,” said Dr. Paul Chew, chief medical and science officer for Sanofi-Aventis in the United States .
More at NYTimes
What are your comments and experienced on Dronedarone?
Birthdays
Birthdays Today
Badge
CardiologyLinks.NET
Journal Scan: Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Be
The Heart
JACC
BMJ Heart
EHJ
NEJM Cardiology
© 2010 Created by Cardiology Rounds Team
